Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it has resumed its pivotal study of Omnipod, Powered by Horizon™, the Company’s personal smart-phone controlled automated insulin delivery system. The Company paused the study, which was approximately halfway through completion, in March.
“We are thrilled to continue our trial,” said Dr. Trang Ly MBBS FRACP PhD, Senior Vice President, Medical Director. “We have encouraging data from our clinical work to date and overwhelmingly positive feedback from participants and investigators. We are excited about what our next-generation Omnipod, Powered by Horizon, will offer people living with diabetes.”
Insulet expects to commercialize Omnipod, Powered by Horizon, in the U.S. in the first half of 2021, pending clearance by the FDA.